Purpose This study was to evaluate the efficacy and toxicity of stereotactic body radiotherapy using Cyberknife in the treatment of patients with liver metastasis.Patients and Methods Between August 2006 and July 2011, 83 liver metastases from eligible 60 patients with different primary carcinoma were treated with Cyberknife at Cancer Hospital & Institute of Tianjin Medical University.The gross target volume (GTV) was defined as liver metastasis, and the clinical target volume (CTV) included the GTV with a 0.5-cm margin.The median prescription dose was 42 Gray(Gy)/3 fractions (21-54Gy/3-7 fractions), and the median biologic equality dose (BED) was 100 Gy(35.7Gy～112.5Gy) according to linear-quadratic (LQ) model.Toxicities were evaluated with the Common Terminology Criteria for Adverse Events version 4.0.Results The 1-year and 2-year local control (LC) rates were 95％ and 90％, respectively.There was significant differences in the LC between the patients receiving adjuvant treatment before Cyberknief and those not receiving (x2 =3.882, p =0.049).For the whole cohort, the median overall survival (OS) was 14.6 months.The median survival was 18.5 months and the 2-year OS rate were 66％ in the favorable group,respectively, however, in the unfavorable group, the median OS was 8.7 months and the 2-year OS rate were 18％, respectively (x2 =14.11, p ＜ 0.001).Grade 1 to 2 fatigue, nausea, and vomit were the most common adverse events, and Grade 3 and higher adverse events were not observed in all patient.Conclusions With excellent level of LC without severe toxicities, stereotactic body radiotherapy using Cyberknief provides an alternative for patients with 1 to 3 liver metastases who cannot undergo surgery and other treatments.